Inotiv, Inc. Stock price

Equities

NOTV

US45783Q1004

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
8.95 USD -1.97% Intraday chart for Inotiv, Inc. +17.30% +143.87%
Sales 2024 * 581M Sales 2025 * 602M Capitalization 231M
Net income 2024 * -29M Net income 2025 * -27M EV / Sales 2024 * 0.4 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.38 x
P/E ratio 2024 *
-7.78 x
P/E ratio 2025 *
-8.44 x
Employees 2,005
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.97%
1 week+5.67%
Current month+20.13%
1 month+49.67%
3 months+185.03%
6 months+172.04%
Current year+143.87%
More quotes
1 week
7.39
Extreme 7.3901
9.70
1 month
5.11
Extreme 5.11
9.70
Current year
3.18
Extreme 3.18
9.70
1 year
1.61
Extreme 1.61
9.70
3 years
1.61
Extreme 1.61
60.66
5 years
1.61
Extreme 1.61
60.66
10 years
0.60
Extreme 0.6
60.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 19-01-11
Director of Finance/CFO 59 20-03-05
Chief Operating Officer 58 21-02-14
Members of the board TitleAgeSince
Director/Board Member 68 17-07-31
Director/Board Member 68 23-01-23
Chairman 70 17-06-13
More insiders
Date Price Change Volume
24-03-18 8.95 -1.97% 839,779
24-03-15 9.13 +10.40% 604,185
24-03-14 8.27 -0.12% 254,865
24-03-13 8.28 -1.31% 411,118
24-03-12 8.39 +9.96% 387,897

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Inotiv, Inc. is an international contract research company that is providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Its DSA segment supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Its RMS segment offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.95 USD
Average target price
18.25 USD
Spread / Average Target
+103.91%
Consensus
  1. Stock
  2. Equities
  3. Stock Inotiv, Inc. - Nasdaq